Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15627404 | 0.94 | KDM4E (0.49) | CYP2D6CYP3A4BRAFLTA4HSMN1; SMN2 | |
| SCHEMBL12568190 | 0.94 | KDM4E (0.49) | CYP2D6CYP3A4BRAFLTA4HSMN1; SMN2 | |
| SCHEMBL4807357 | 0.94 | KDM4E (0.49) | CYP2D6CYP3A4BRAFLTA4HSMN1; SMN2 | |
| SCHEMBL525095 | 0.88 | CYP2D6 (0.56) | CYP2D6CYP3A4LTA4HSMN1; SMN2LMNA | |
| SCHEMBL8339774 | 0.83 | MAPT (0.52) | LTA4HKDM4ERAB9AMAPTRECQL | |
| SCHEMBL12743776 | 0.80 | CYP2D6 (0.59) | CYP2D6CYP3A4LTA4HSMN1; SMN2LMNA | |
| SCHEMBL11245903 | 0.79 | CYP2D6 (0.64) | CYP2D6CYP3A4LTA4HSMN1; SMN2LMNA | |
| SCHEMBL7947076 | 0.77 | CYP2D6 (0.81) | CYP2D6CYP3A4LTA4HSMN1; SMN2LMNA | |
| SCHEMBL22285824 | 0.77 | MAOA (0.37) | KDM4ETSHRRECQLMAOADYRK1A | |
| SCHEMBL15223391 | 0.77 | CCR1 (0.61) | CYP2D6CYP1A2CYP2C19MAOADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107501275-B | It can be used as the compound of ATR kinase inhibitor | Votex Pharmaceutical Co., Ltd. (US) | 2019-11-22 | — | — | CN | disclosed |
| CN-107501274-B | It can be used as the compound of ATR kinase inhibitor | Votex Pharmaceutical Co., Ltd. (US) | 2019-11-22 | — | — | CN | disclosed |
| CN-109608449-A | Compound as type III receptor tyrosine kinase inhibitors | 阵列生物制药公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-105924437-B | Compound as type III receptor tyrosine kinase inhibitors | 阵列生物制药公司 | 2018-11-30 | — | — | CN | disclosed |
| EP-2542552-B1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-15 | — | — | EP | disclosed |
| US-9718820-B2 | Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-01 | — | — | US | disclosed |
| CN-104066730-B | Heterocyclic compounds and their use as type III receptor tyrosine kinase modulators | 埃姆比特生物科学公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20160304518-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-20 | — | — | US | disclosed |
| US-9409915-B2 | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-09 | — | — | US | disclosed |
| CN-105189515-A | Furopyridines as bromodomain inhibitors | GLAXOSMITHKLINE IP NO 2 LTD | 2015-12-23 | — | — | CN | disclosed |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-08 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| US-7452951-B2 | Multifunctional self-decontaminating surface coating | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080102281-A1 | MULTIFUNCTIONAL SELF-DECONTAMINATING SURFACE COATING | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7339015-B2 | Multifunctional self-decontaminating surface coating | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070122438-A1 | Multifunctional self-decontaminating surface coating | THE GOVERNMENT OF THE UNITED STATES, AS RESPRESENTED BY THE SECRETARY OF THE NAVY | 2007-05-31 | — | — | US | disclosed |
| EP-0074653-B1 | NEW CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
| EP-0231475-A1 | Process for preparing intermediate products and their use for preparing cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-08-12 | — | — | EP | disclosed |
| US-4521413-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-04 | — | — | US | disclosed |
| EP-0074653-A2 | New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and intermediate products for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304518-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | CYP2D6 3292/4885CYP3A4 3186/4885BRAF 2287/4885 |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | CYP2D6 3014/4885CYP3A4 4362/4885BRAF 594/4885 |
| US-20070122438-A1 | Multifunctional self-decontaminating surface coating | YWHAZ, EPCAM, LBR | CYP2D6 3645/4885CYP3A4 3092/4885BRAF 3585/4885 |
| US-20110218197-A1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | CYP2D6 3292/4885CYP3A4 3186/4885BRAF 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.